Nms Group

NMS Group, Italy's largest oncology-focused R&D company, employs over 400 individuals, with more than half in advanced research and manufacturing roles. Its kinase inhibitor and antibody-conjugate platforms drive innovation, establishing NMS as a global leader in personalized therapies. Notably, NMS discovered entrectinib, a targeted kinase inhibitor for NTRK1/2/3 and ROS1-dependent tumors, now commercialized globally through Roche. The Group includes three subsidiaries: NMS S.r.l, focused on FIC/BIC cancer drug development with a dozen active projects; Accelera, a preclinical CRO; and NerPharMa, which manufactures APIs and drug products for clinical and commercial use.